{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:11Z","timestamp":1790810051448,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Imiqualines family is an original group of small heterocyclic compounds, diversely substituted around different scaffolds. Among these compounds, the lead EAPB02303 displays outstanding cytotoxic activity at nanomolar concentrations comparable to those of standard-of-care chemotherapy drugs in different cancer cell lines, including Pancreatic Ductal AdenoCarcinoma (PDAC) cell lines. Due to its high aggressiveness and resistance to therapies, PDAC has an extremely poor prognosis with limited treatment options. Here, we demonstrated the cytotoxic activities of EAPB02303 alone or combined with standard chemotherapy drugs in several PDAC cell lines and confirmed these results in patient-derived xenograft mouse models. EAPB02303 potently induced cell cycle arrest in the G2\/M phase and in mitosis followed by apoptosis. Then, using a combination of transcriptomic, proteomic, biochemical and cellular assay, we found that EAPB02303 mechanism of action relies on its bioactivation by catechol-O-methyltransferase, resulting in the production of a methylated compound that effectively inhibits microtubule polymerization. Moreover, EAPB02303 had a synergistic effect when combined with paclitaxel (the standard-of-care agent in PDAC) providing the rationale to continue the development of EAPB02303 combination strategies for the treatment of catechol-O-methyltransferase-overexpressing PDAC.<\/jats:p>","DOI":"10.1038\/s41419-025-07747-1","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:37:10Z","timestamp":1749469030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer models"],"prefix":"10.1038","volume":"16","author":[{"given":"K\u00e9vin","family":"Bigot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Patinote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Garambois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Chouchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gayraud-Paniagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Vie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Maggipinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Smyej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Machu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bruciamacchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-0593","authenticated-orcid":false,"given":"Corinne","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Mathonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Levy-Aug\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antoine","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-4031","authenticated-orcid":false,"given":"C\u00e9line","family":"Gongora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-5178","authenticated-orcid":false,"given":"Carine","family":"Deleuze-Masqu\u00e9fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8531-9552","authenticated-orcid":false,"given":"Christel","family":"Larbouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"7747_CR1","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1182\/blood-2007-11-121913","volume":"111","author":"G Moarbess","year":"2008","unstructured":"Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, et al. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I\u2013associated adult T-cell leukemia\/lymphoma. Blood. 2008;111:3770\u20137.","journal-title":"Blood"},{"key":"7747_CR2","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1016\/j.ejmech.2009.02.007","volume":"44","author":"C Deleuze-Masquefa","year":"2009","unstructured":"Deleuze-Masquefa C, Moarbess G, Khier S, David N, Gayraud-Paniagua S, Bressolle F, et al. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma. Eur J Med Chem. 2009;44:3406\u201311.","journal-title":"Eur J Med Chem"},{"key":"7747_CR3","doi-asserted-by":"publisher","first-page":"e0182022","DOI":"10.1371\/journal.pone.0182022","volume":"12","author":"A Courbet","year":"2017","unstructured":"Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, et al. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS One. 2017;12:e0182022.","journal-title":"PLoS One"},{"key":"7747_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113031","volume":"212","author":"C Patinote","year":"2021","unstructured":"Patinote C, Deleuze-Masqu\u00e9fa C, Kaddour KH, Vincent LA, Larive R, Zghaib Z, et al. Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. Eur J Med Chem. 2021;212:113031.","journal-title":"Eur J Med Chem"},{"key":"7747_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jpba.2017.10.025","volume":"148","author":"A Chouchou","year":"2018","unstructured":"Chouchou A, Marion B, Enjalbal C, Roques C, Cuq P, Bonnet PA, et al. Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2018;148:369\u201379.","journal-title":"J Pharm Biomed Anal"},{"key":"7747_CR6","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321.","journal-title":"Cancer Res"},{"key":"7747_CR7","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846\u201361.","journal-title":"World J Gastroenterol"},{"key":"7747_CR8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"7747_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s10637-018-0598-5","volume":"36","author":"J Kang","year":"2018","unstructured":"Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest N. Drugs. 2018;36:732\u201341.","journal-title":"Invest N. Drugs"},{"key":"7747_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/0092-8674(81)90072-6","volume":"25","author":"DW Cleveland","year":"1981","unstructured":"Cleveland DW, Lopata MA, Sherline P, Kirschner MW. Unpolymerized tubulin modulates the level of tubulin mRNAs. Cell. 1981;25:537\u201346.","journal-title":"Cell"},{"key":"7747_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ceb.2013.07.003","volume":"25","author":"CH Topham","year":"2013","unstructured":"Topham CH, Taylor SS. Mitosis and apoptosis: how is the balance set? Current Opin Cell Biol. 2013;25:780\u20135.","journal-title":"Current Opin Cell Biol"},{"key":"7747_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/med.20242","volume":"31","author":"RA Stanton","year":"2011","unstructured":"Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31:443\u201381.","journal-title":"Med Res Rev"},{"key":"7747_CR13","doi-asserted-by":"publisher","first-page":"a022608","DOI":"10.1101\/cshperspect.a022608","volume":"10","author":"HV Goodson","year":"2018","unstructured":"Goodson HV, Jonasson EM. Microtubules and microtubule-associated proteins. Cold Spring Harb Perspect Biol. 2018;10:a022608.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"7747_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","volume":"28","author":"MO Steinmetz","year":"2018","unstructured":"Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 2018;28:776\u201392.","journal-title":"Trends Cell Biol"},{"key":"7747_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ph13010008","volume":"13","author":"EC McLoughlin","year":"2020","unstructured":"McLoughlin EC, O\u2019Boyle NM. Colchicine-binding site inhibitors from chemistry to clinic: a review. Pharmaceuticals. 2020;13:8.","journal-title":"Pharmaceuticals"},{"key":"7747_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"7747_CR17","doi-asserted-by":"publisher","first-page":"11263","DOI":"10.3390\/ijms241411263","volume":"24","author":"S Zoroddu","year":"2023","unstructured":"Zoroddu S, Sanna L, Bordoni V, Lyu W, Murineddu G, Pinna GA, et al. RNAseq analysis of novel 1,3,4-oxadiazole chalcogen analogues reveals anti-tubulin properties on cancer cell lines. Int J Mol Sci. 2023;24:11263.","journal-title":"Int J Mol Sci"},{"key":"7747_CR18","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-18-3281","volume":"25","author":"JA Eberle-Singh","year":"2019","unstructured":"Eberle-Singh JA, Sagalovskiy I, Maurer HC, Sastra SA, Palermo CF, Decker AR, et al. Effective delivery of a microtubule polymerization inhibitor synergizes with standard regimens in models of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25:5548\u201360.","journal-title":"Clin Cancer Res"},{"key":"7747_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"7747_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.969183","volume":"13","author":"L Lafanech\u00e8re","year":"2022","unstructured":"Lafanech\u00e8re L. The microtubule cytoskeleton: an old validated target for novel therapeutic drugs. Front Pharm. 2022;13:969183.","journal-title":"Front Pharm"},{"key":"7747_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55526-8","volume":"9","author":"A Langeb\u00e4ck","year":"2019","unstructured":"Langeb\u00e4ck A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, et al. CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Sci Rep. 2019;9:19384.","journal-title":"Sci Rep"},{"key":"7747_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1126\/science.aan0346","volume":"359","author":"CSH Tan","year":"2018","unstructured":"Tan CSH, Go KD, Bisteau X, Dai L, Yong CH, Prabhu N, et al. Thermal proximity coaggregation for system-wide profiling of protein complex dynamics in cells. Science. 2018;359:1170\u20137.","journal-title":"Science"},{"key":"7747_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15384101.2018.1559557","volume":"18","author":"D Sinha","year":"2019","unstructured":"Sinha D, Duijf PHG, Khanna KK. Mitotic slippage: an old tale with a new twist. Cell Cycle. 2019;18:7.","journal-title":"Cell Cycle"},{"key":"7747_CR24","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v14.i2.92558","volume":"14","author":"O Oey","year":"2024","unstructured":"Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: current insights and therapeutic perspectives. World J Exp Med. 2024;14:92558.","journal-title":"World J Exp Med"},{"key":"7747_CR25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule targeting agent. Clin Cancer Res. 2015;21:2445\u201352.","journal-title":"Clin Cancer Res"},{"key":"7747_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12640-017-9729-6","volume":"32","author":"SJ Benbow","year":"2017","unstructured":"Benbow SJ, Wozniak KM, Kulesh B, Savage A, Slusher BS, Littlefield BA, et al. Microtubule targeting agents eribulin and paclitaxel differentially affect neuronal cell bodies in chemotherapy induced peripheral neuropathy. Neurotox Res. 2017;32:151\u201362.","journal-title":"Neurotox Res"},{"key":"7747_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/13543776.2023.2291390","volume":"33","author":"MN Peerzada","year":"2023","unstructured":"Peerzada MN, Dar MS, Verma S. Development of tubulin polymerization inhibitors as anticancer agents. Expert Opin Ther Pat. 2023;33:797\u2013820.","journal-title":"Expert Opin Ther Pat"},{"key":"7747_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.COC.0000071385.65898.88","volume":"27","author":"JP Spano","year":"2004","unstructured":"Spano JP, Bouillet T, Boaziz C, Piperno-Neumann S, Brunel P, Hennebelle F, et al. Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol. 2004;27:317.","journal-title":"Am J Clin Oncol"},{"key":"7747_CR29","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/cancers12082196","volume":"12","author":"L Peronne","year":"2020","unstructured":"Peronne L, Denarier E, Rai A, Prudent R, Vernet A, Suzanne P, et al. Two antagonistic microtubule targeting drugs act synergistically to kill cancer cells. Cancers. 2020;12:2196.","journal-title":"Cancers"},{"key":"7747_CR30","doi-asserted-by":"crossref","unstructured":"Jiao M, Pirozzi CJ, Yu C, Bao X, Hu M, Pan D, et al. Targeting Catechol-O-methyltransferase induces mitochondrial dysfunction and enhances the efficacy of radiotherapy in glioma. Cancer Res. 2024;84:3640\u201356.","DOI":"10.1158\/0008-5472.CAN-24-0134"},{"key":"7747_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/cas.12648","volume":"106","author":"W Wu","year":"2015","unstructured":"Wu W, Wu Q, Hong X, Zhou L, Zhang J, You L, et al. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Cancer Sci. 2015;106:576\u201383.","journal-title":"Cancer Sci"},{"key":"7747_CR32","first-page":"535","volume":"48","author":"WM Wu","year":"2010","unstructured":"Wu WM, Zhao YP, Liao Q, Zhang TP. The expression of catechol O-methyltransferase gene in colorectal cancer. Zhonghua Wai Ke Za Zhi. 2010;48:535\u20138.","journal-title":"Zhonghua Wai Ke Za Zhi"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07747-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:37:14Z","timestamp":1749469034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07747-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7747"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07747-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were approved by the Ethics Committee (Protocol number No. C34-172-27) at IRCM animal house in Montpellier following the national guidelines. This study was approuved by the local ethics committees of IRC in compliance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"441"}}